دورية أكاديمية
Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.
| العنوان: | Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM. |
|---|---|
| المؤلفون: | Lübke J; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Schmid A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Christen D; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.; Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf, Aachen, Germany., Oude Elberink HNG; Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Span LFR; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Niedoszytko M; Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland., Gorska A; Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland., Lange M; Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland., Gleixner KV; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Hadzijusufovic E; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.; Department/University Clinic for Companion Animals and Horses, Internal Medicine Small Animals, University Clinic for Small Animals, University of Veterinary Medicine, Vienna, Austria., Stefan A; University Clinic for Hematology and Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria., Angelova-Fischer I; Department of Dermatology and Venereology, Allergy Center, Kepler University Hospital, Johannes Kepler University, Linz, Austria., Zanotti R; Department of Medicine, Section of Hematology, Verona University Hospital, Verona, Italy., Bonifacio M; Department of Medicine, Section of Hematology, Verona University Hospital, Verona, Italy., Bonadonna P; Allergy Unit, Verona University Hospital, Verona, Italy., Shoumariyeh K; Department of Medicine I, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany., von Bubnoff N; Department of Medicine I, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany., Müller S; Department of Dermatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Perkins C; Stanford Cancer Institute, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA., Elena C; Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Malcovati L; Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Hagglund H; Division of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Mattsson M; Division of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Parente R; Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy., Varkonyi J; Department of Hematology, Semmelweis University, Budapest, Hungary., Fortina AB; Department of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy., Caroppo F; Department of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy., Brockow K; Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany., Zink A; Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany., Breynaert C; KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, University Hospitals Leuven, Leuven, Belgium., Leven T; KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, University Hospitals Leuven, Leuven, Belgium., Yavuz AS; Division of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey., Doubek M; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic., Sabato V; Department of Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium., Schug T; Department of Dermatology and Venereology, University Hospital Graz, Graz, Austria., Hartmann K; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Triggiani M; Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy., Gotlib J; Stanford Cancer Institute, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA., Hermine O; French Reference Center for Mastocytosis, Hospital Necker, Assistance Publique Hôpitaux de Paris, Imagine Institute, University Paris Descartes, Paris, France., Arock M; French Reference Center for Mastocytosis, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, University Paris Sorbonne, Paris, France., Kluin-Nelemans HC; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Panse J; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.; Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf, Aachen, Germany., Sperr WR; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Valent P; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Reiter A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Schwaab J; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. |
| المصدر: | Blood advances [Blood Adv] 2024 Jun 11; Vol. 8 (11), pp. 2890-2900. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, DC : American Society of Hematology, [2016]- |
| مواضيع طبية MeSH: | Mastocytosis, Systemic*/diagnosis , Mastocytosis, Systemic*/blood , Registries*, Humans ; Prognosis ; Male ; Female ; Middle Aged ; Adult ; Aged ; Biomarkers/blood ; Tryptases/blood |
| مستخلص: | Abstract: Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, β2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein (P < .001). With regard to subvariants of AdvSM, an elevated LDH of ≥260 U/L was associated with multilineage expansion (leukocytosis, r = 0.37, P < .001; monocytosis, r = 0.26, P < .001) and the presence of an associated myeloid neoplasm (P < .001), whereas tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308μg/L vs 146μg/L, P = .003). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .018) and 1.5 points each to β2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; P = .004) and albumin (HR, 3.3; 95% CI, 1.7-6.5; P = .001) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; ≥1.5 points, 1.7 years; P < .001). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score (P = .027). In conclusion, serum chemistry profiling is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants. (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.) |
| References: | Immunol Allergy Clin North Am. 2018 Aug;38(3):483-495. (PMID: 30007465) Eur J Clin Invest. 2009 Oct;39(10):914-23. (PMID: 19522836) J Allergy Clin Immunol Pract. 2020 Oct;8(9):3121-3127.e1. (PMID: 32422371) Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):814-821. (PMID: 30642843) Leukemia. 2015 May;29(5):1115-22. (PMID: 25567135) J Allergy Clin Immunol. 2015 Mar;135(3):792-8. (PMID: 25129675) Wien Klin Wochenschr. 2004 Oct 30;116(19-20):647-51. (PMID: 15941072) Australas J Dermatol. 2015 Feb;56(1):7-13. (PMID: 24575854) Expert Opin Biol Ther. 2021 Apr;21(4):487-498. (PMID: 33063554) Blood. 2009 Jun 4;113(23):5727-36. (PMID: 19363219) Int J Mol Sci. 2020 Nov 27;21(23):. (PMID: 33261124) Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. (PMID: 23179435) Exp Oncol. 2019 Dec;41(4):357-362. (PMID: 31868326) Lancet Haematol. 2019 Dec;6(12):e638-e649. (PMID: 31676322) Leukemia. 2016 Dec;30(12):2342-2350. (PMID: 27416984) Leukemia. 2015 Jun;29(6):1223-32. (PMID: 25650093) J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87. (PMID: 30416055) J Allergy Clin Immunol Pract. 2022 Aug;10(8):1953-1963. (PMID: 35283331) Stat Med. 1982 Apr-Jun;1(2):121-9. (PMID: 7187087) Leuk Res. 2001 Jul;25(7):603-25. (PMID: 11377686) Ann Hematol. 2014 Jan;93(1):81-8. (PMID: 24281161) Blood Adv. 2018 Nov 13;2(21):2964-2972. (PMID: 30413432) Br J Haematol. 2021 Jul;194(2):344-354. (PMID: 34060083) Eur J Clin Invest. 2016 May;46(5):392-7. (PMID: 26914980) J Clin Oncol. 2019 Nov 1;37(31):2846-2856. (PMID: 31509472) Nat Med. 2021 Dec;27(12):2192-2199. (PMID: 34873345) Leukemia. 2022 Feb;36(2):516-524. (PMID: 34545185) Leukemia. 2020 Apr;34(4):1090-1101. (PMID: 31740811) Nat Med. 2021 Dec;27(12):2183-2191. (PMID: 34873347) Leukemia. 2016 Jan;30(1):136-43. (PMID: 26464169) Hemasphere. 2021 Oct 13;5(11):e646. (PMID: 34901755) J Mol Diagn. 2011 Mar;13(2):180-8. (PMID: 21354053) N Engl J Med. 2016 Jun 30;374(26):2530-41. (PMID: 27355533) Pathology. 2017 Jun;49(4):413-418. (PMID: 28549721) J Natl Cancer Inst. 2013 Dec 4;105(23):1799-805. (PMID: 24249744) J Clin Oncol. 2022 Jun 1;40(16):1783-1794. (PMID: 35235417) Blood. 2013 Oct 3;122(14):2460-6. (PMID: 23958953) Blood. 2017 Mar 16;129(11):1420-1427. (PMID: 28031180) Lancet Haematol. 2021 Mar;8(3):e194-e204. (PMID: 33508247) Blood. 2020 Apr 16;135(16):1365-1376. (PMID: 32106312) Haematologica. 2017 Jun;102(6):1035-1043. (PMID: 28255023) Int J Mol Sci. 2021 Mar 04;22(5):. (PMID: 33806359) |
| معلومات مُعتمدة: | P 32470 Austria FWF_ Austrian Science Fund FWF |
| المشرفين على المادة: | 0 (Biomarkers) EC 3.4.21.59 (Tryptases) |
| تواريخ الأحداث: | Date Created: 20240409 Date Completed: 20240605 Latest Revision: 20240731 |
| رمز التحديث: | 20240731 |
| مُعرف محوري في PubMed: | PMC11214361 |
| DOI: | 10.1182/bloodadvances.2024012756 |
| PMID: | 38593217 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2473-9537 |
|---|---|
| DOI: | 10.1182/bloodadvances.2024012756 |